REUTERS/Evelyn Hockstein/File PhotoWILMINGTON, Delaware, June 29 (Reuters) - A prominent U.S. lawsuit to ban the abortion pill mifepristone has focused on the drug's safety and approval process.
Skop and 10 other doctors submitted their testimony when the case began in November.
She said she was harmed by the FDA expanding access to the pill because she has treated dozens of women at her hospital's emergency room with mifepristone complications.
Erin Hawley, an attorney with the Alliance Defending Freedom legal organization representing the plaintiffs, said abortion sets the case apart.
In the abortion pill case, the two initial court rulings found harm to Skop and other doctors was "impending" because the mifepristone label says the treatment may be unsuccessful in up 7% of women.
Persons:
Evelyn Hockstein, mifepristone, Ingrid Skop, Roe, Wade, Skop, doesn’t, Leah Litman, Erin Hawley, Hawley, Matthew Kacsmaryk, Samuel Alito's, Danco, Tom Hals, Amy Stevens, Deepa Babington
Organizations:
Alamo Women's, REUTERS, U.S . Food, Drug Administration, Supreme, FDA, University of Michigan Law School, Alliance Defending, Alliance for Hippocratic, District, Appeals, U.S, Fifth, Amnesty International, Danco Laboratories, Thomson
Locations:
Carbondale , Illinois, U.S, WILMINGTON , Delaware, Texas, America, Amarillo , Texas, Amarillo, New Orleans, Louisiana, United States, Wilmington , Delaware